Insider Transactions in Q2 2023 at Akebia Therapeutics, Inc. (AKBA)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 06
2023
|
Steven C Gilman |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+25.61%
|
-
|
|
Jun 06
2023
|
Cynthia Smith |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+23.96%
|
-
|
|
Jun 06
2023
|
Adrian Adams |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+18.2%
|
-
|
|
Jun 06
2023
|
Myles Wolf |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+30.71%
|
-
|
|
Jun 06
2023
|
Ron Frieson |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+40.71%
|
-
|
|
Jun 06
2023
|
Michael W Rogers |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+23.8%
|
-
|
|
Jun 06
2023
|
Leanne M Zumwalt |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+40.71%
|
-
|
|
May 25
2023
|
Michel Dahan SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
95,478
-14.26%
|
$95,478
$1.22 P/Share
|
|
May 25
2023
|
Nicole R. Hadas SVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
63,186
-10.75%
|
$63,186
$1.22 P/Share
|
|
May 24
2023
|
Michel Dahan SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+23.0%
|
-
|
|
May 24
2023
|
Nicole R. Hadas SVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+25.4%
|
-
|
|
May 16
2023
|
David A Spellman SVP, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
63,567
-12.46%
|
$63,567
$1.07 P/Share
|
|
May 16
2023
|
Steven Keith Burke SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
63,567
-10.7%
|
$63,567
$1.07 P/Share
|
|
May 12
2023
|
Michel Dahan SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+29.87%
|
-
|
|
May 12
2023
|
Nicole R. Hadas SVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+20.51%
|
-
|